Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 10000
Country/Region: Vietnam
Year: 2017
Main Partner: Harvard University
Main Partner Program: Harvard Medical School (Harvard Medical School AIDS Initiative in Vietnam)
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $1,451,997 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $34,300
Care: TB/HIV (HVTB) $48,020
Care: Pediatric Care and Support (PDCS) $6,860
Health Systems Strengthening (OHSS) $86,333
Testing: HIV Testing and Counseling (HVCT) $0
Treatment: Adult Treatment (HTXS) $1,176,432
Treatment: Pediatric Treatment (PDTX) $100,052
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TB_PREV By Age/Sex (Numerator): <15, Female 2018 29
TB_PREV By Age/Sex (Numerator): <15, Male 2018 35
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 625
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 1,090
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 1,779
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 2,222
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 38
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 42
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 785
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 1,357
TX_CURR Aggregated Age/Sex: <15 Female 2018 409
TX_CURR Aggregated Age/Sex: <15 Male 2018 459
TX_CURR Aggregated Age/Sex: 15+ Female 2018 8,000
TX_CURR Aggregated Age/Sex: 15+ Male 2018 13,589
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 22,457
TX_CURR Sum of Aggregated Age/Sex <15 2018 868
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 21,589
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 22,457
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 46
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 53
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 979
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 1,699
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 2,777
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 2,777
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 19,875
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 17,885
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 325
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 365
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 6,380
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 10,815
TX_PVLS Numerator: Indication: Routine 2018 17,885
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 359
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 402
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 7,105
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 12,009
TX_PVLS_den Denominator: Indication: Routine 2018 19,875
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 38
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 45
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 811
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,412
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 2,306
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 2,502
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 40
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 48
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 884
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,530
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 21,336
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 414
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 7
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 7
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 152
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 248
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 386
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 435
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 7,606
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 12,909